Gadobutrol

Last updated
Gadobutrol
Gadobutrol skeletal.svg
Clinical data
AHFS/Drugs.com International Drug Names
License data
Routes of
administration 		IV
ATC code
Legal status
Legal status
Identifiers
  • gadolinium(III) 2,2',2''-(10-((2R,3S)-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
Formula C18H31GdN4O9
Molar mass 604.72 g·mol−1
3D model (JSmol)
  • C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])[C@@H](CO)[C@H](CO)O)CC(=O)[O-].[Gd+3]
  • InChI=1S/C18H34N4O9.Gd/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3/t14-,15-;/m0./s1
  • Key:ZPDFIIGFYAHNSK-YYLIZZNMSA-K
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).

Contents

It received marketing approval in Canada and the United States. [2] [3] [4] [5] As of 2007, it was the only GBCA approved at 1.0 molar concentrations. [6]

Gadobutrol is marketed by Bayer AG as Gadovist, by Bayer HealthCare Pharmaceuticals as Gadavist, [7] and by GE HealthCare as PixxoScan. In India, it is also marketed by Vivere Imaging as Viv-butrol. [8]

Medical uses

Gadobutrol is a medicinal product used in diagnostic magnetic resonance imaging (MRI) in adults and children. It provides contrast enhancement during cranial, spinal, breast, or other investigations. In the central nervous system, Gadobutrol works by highlighting any areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity. In breast tissue, Gadobutrol exposes the presence and extent of malignant breast disease. Similarly, gadobutrol is also used in contrast-enhanced magnetic resonance angiography (CE-MRA) for the diagnosis of stroke, detection of tumor perfusion, and presence of focal cerebral ischemia. [7] [9]

Gadobutrol should be administered intravenously by medical professionals only. Sterile techniques must always be used when preparing and administering the injection. When compared to other GBCAs, Gadobutrol is available in a more concentrated form (1 mmol/mL) to alleviate a high volume of administration. The recommended dose is 0.1 mL/kg body weight. [7]

Adverse effects

The safety of gadobutrol was assessed throughout clinical trials and post-marketing, for multiple applications, in diverse populations and at multiple doses. [7] [9]

The most severe reaction to gadobutrol is nephrogenic system fibrosis (NSF) among patients with impaired elimination of the drug. The risk is highest among patients with chronic, impaired kidney function and those with acute kidney injury. NSF may result in death or severe impairment of the skin, muscle, and internal organs. [7]

Patients who have experienced a previous adverse reaction to another contrast agent, have bronchial asthma, and/or allergic disorders have an increased risk of a hypersensitivity reaction to gadobutrol. Hypersensitivity reactions can include anaphylactoid and anaphylactic reactions ranging from mild to severe. These reactions are uncommon, however, monitoring of the patient for signs and symptoms during and after administration of gadobutrol is necessary. [7] [9]

Other, more mild adverse reactions have been observed in a small fraction of patients after administration. These reactions can include but are not limited to the following: [7]

Use in specific populations

Pregnancy

The FDA has labeled gadobutrol as pregnancy category C. Sufficient studies of gadobutrol in pregnant human females have not been conducted. However, other GBCAs have been shown to cross the placenta in humans and result in fetal exposure, but do not show adverse effects to the fetus. [7]

Animal studies have been conducted in which pregnant rats and rabbits were exposed to 12 and 8 times the human equivalent dose based on body surface area respectively. These exposures often resulted in retardation of the embryo development and embryo death. Embryo retardation did not occur in monkeys administered up to 8 times the recommended human dose but did result in embryo death. The animals were administered multiple doses repeatedly over days, therefore, their exposure levels were much higher than those experienced in humans. [7]

Gadobutrol should only be administered in pregnant females if the potential benefit outweighs the risk to the fetus. [7] [9]

Breast-feeding

It is unknown the amount of Gadobutrol transferred to milk in humans. Limited data exists on the excretion of other GBCAs in human breast milk, but suggest a transfer rate of 0.01% to 0.04% of the administered material to breast milk. Non-clinical data for Gadrobutrol suggests that less than 0.01% is excreted into breast milk upon intravenous administration of the recommended dose. Further data suggests that absorption via the GI tract is very poor (approximately 5%). For the highest level of safety, breastfeeding should be discontinued for 24 hours upon administration of gadobutrol and any milk properly disposed of. [7] [9]

Pediatrics

The safety, efficacy, and pharmacokinetics have been well established in children ages 2–17 years. It was found that no adjustment of the recommended 0.1 mL/kg body weight dose was necessary. [7] [9]

The safety and efficacy data for children under the age of 2 years is limited but has demonstrated that use of the 0.1 mL/kg body weight dose may be used in this population. However, it is recommended that the lowest possible dose be utilized and that a period of at least 7 days in between doses be allowed for elimination of the agent from the body. [9]

Geriatrics

Clinical data has shown that there is no difference in the safety or efficacy of gadobutrol in subjects of 65 years and older when compared with those under the age of 65 years. There are no required special precautions and/or dose adjustment for those without renal impairment. [7] [9]

Renally impaired population

It is recommended that renal impairment be assessed for all patients prior to administration of gadobutrol. It is not necessary to adjust the dose in these populations, however, gadobutrol will need to be removed from the body using hemodialysis. [7]

Interactions

There are no known drug interactions with gadobutrol. However, it should not be mixed with other drugs. [7]

Mechanism of action

Gadobutrol is a paramagnetic macrocyclic contrast agent administered intravenously for use in magnetic resonance imaging. The contrast-enhancing effect is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol), which works to decrease differences in longitudinal relaxation times (T1) and differences in spin-spin or transverse relaxation times (T2). These relaxation times, coupled with differences in proton density, are responsible for the variation in intensity of radio frequency signals which contribute to an MRI's tissue visualization capabilities. Greater signal enhancement, and therefore, greater tissue visualization, is achieved with increased shortening of T1 and T2. [9] [10]

History

Commercialization

Gadobutrol was first approved in Switzerland in 1998 for use in contrast-enhanced MRI scans of the brain and spinal cord. Since then, it has been approved and marketed in 65 other countries including all European Union countries, the United States, Canada, Mexico, Australia, New Zealand, China, South Korea, Russia, and Brazil, for a multitude of uses. [11] Gadobutrol was first approved for use in MRIs of the central nervous system in the United States in 2011. It is currently manufactured by Bayer Healthcare Pharmaceuticals Inc. and marketed under the brand name Gadavist. [11] [12] In 2015, Gadavist was approved by the FDA as the first contrast agent safe for use in children under the age of 2 years old. Most recently, in early 2016, Gadavist was approved in the United States for use in contrast-enhanced magnetic resonance angiography. [12]

Research and clinical trials

Gadavist was approved in the United States in 2011 after presenting findings from 43 clinical studies that had primarily taken place in Asia and the European Union, in addition to one phase 2 and two phase 3 clinical trials conducted in the United States. [11] The multi-center, randomized, double-blind phase 3 clinical trials (one completed without the active comparator arm) [13] enrolled 402 patients referred for a contrast-enhanced MRI of the CNS, both male and female, over the age of 18. [14] Each patient received a single dose of gadobutrol (0.1 mmol/kg body weight) via intravenous injection, followed by a single dose of gadoteridol (ProHance) at the approved dose (0.1 mmol/kg body weight) via intravenous injection, or vice versa. The study evaluated safety and efficacy of gadobutrol. From these phase 3 clinical trials, the following conclusions were made: [11]

Prior to approval for use in children under the age of 2 years old in 2015, a phase 1 clinical trial was conducted. Pediatric patients, scheduled for a routine contrast-enhanced MRI examination of any body region, both male and female, under the age of 2 years old could be enrolled in the study. The open-label, multi-center, pharmacokinetic and safety test studied the way gadobutrol was taken into, moved around, and was eliminated from the body of the infants. The study also evaluated safety, tolerability and efficacy of the standard dose of gadobutrol, 0.1 mmol/kg (0.1 mL/kg) of body weight. The clinical trial was sponsored by Bayer Healthcare Pharmaceuticals Inc. [15]

Prior to approval for use in magnetic resonance angiography (MRA) in early 2006, a phase 3 clinical trial was conducted. Patients referred for a routine magnetic resonance angiography (MRA), both male and female, over the age of 18 years old could be enrolled in the study. The open-label, muti-center, blinded reading safety and efficacy study compared diagnostic results of gadobutrol enhanced MRA images with no-contrast MRA images. Patients received a single intravenous injection of 0.1 mmol/kg gadobutrol prior to scanning. The MRA image results were then blindly read by qualified personnel. The clinical trial was sponsored by Bayer Healthcare Pharmaceuticals Inc. [16]

Regulatory

The only US patent for Gadobutrol is US5980864A, granted on November 9, 1999, to Schering AG. [17] The patent is for the process using 1,4,7,10-tetraazacyclododecane butyltriols to produce the gadolinium (III) complex of 10-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane (gadobutrol). The patent defends the use of this metal complex as a superior diagnostic medium. In 2006, Bayer Healthcare Pharmaceuticals Inc. absorbed Schering AG, and in November 2007, the patent was transferred to Bayer Schering Pharma. After FDA approval in 2011, the patent was granted an extension of 1,470 days and the trade name Gadavist became associated with the patent. In February 2016, the patent was granted a second term extension, but expired in Nov 2016. [17]

Packaging and purchasing

Gadobutrol contrast media is a clear, colorless-to-pale yellow solution of 1 mmol/mL formulation, available in single dose vials (2 mL, 7.5 mL, 10mL, and 15 mL), single dose pre-filled injections (7.5 mL, 10 mL, 15 mL), and pharmacy bulk packages (30 mL and 65 mL) containing multiple vials. [18] Gadobutrol is currently marketed in the United States under the name Gadavist, and in most other countries under the name Gadovist or Gadovist 1.0. [11]

Gadobutrol is not available for prescription and can only be administered by trained personnel. In 2016 Bayer-UK published prices for the product. [19]

Related Research Articles

<span class="mw-page-title-main">Desmoteplase</span> Medication

Desmoteplase is a novel, highly fibrin-specific "clot-busting" (thrombolytic) drug in development that reached phase III clinical trials. The Danish pharmaceutical company, Lundbeck, owns the worldwide rights to Desmoteplase. In 2009, two large trials were started to test it as a safe and effective treatment for patients with acute ischaemic stroke. After disappointing results in DIAS-3, DIAS-4 was terminated, and in December 2014 Lundbeck announced that they would stop the development of desmoteplase.

<span class="mw-page-title-main">Cladribine</span> Pharmaceutical drug

Cladribine, sold under the brand name Leustatin, among others, is a medication used to treat hairy cell leukemia and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.

<span class="mw-page-title-main">Asparaginase</span> Enzyme used as medication and in food manufacturing

Asparaginase is an enzyme that is used as a medication and in food manufacturing. As a medication, L-asparaginase is used to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. In food manufacturing it is used to decrease acrylamide.

Iduronidase, sold as Aldurazyme, is an enzyme with the systematic name glycosaminoglycan α-L-iduronohydrolase. It catalyses the hydrolysis of unsulfated α-L-iduronosidic linkages in dermatan sulfate.

<span class="mw-page-title-main">Pegaptanib</span> Drug to treat macular degeneration

Pegaptanib sodium injection is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). It was discovered by NeXstar Pharmaceuticals and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States. Gilead Sciences continues to receive royalties from the drugs licensing. Outside the US pegaptanib is marketed by Pfizer. Approval was granted by the U.S. Food and Drug Administration (FDA) in December 2004.

<span class="mw-page-title-main">Laquinimod</span> Chemical compound

Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease.

MRI contrast agents are contrast agents used to improve the visibility of internal body structures in magnetic resonance imaging (MRI). The most commonly used compounds for contrast enhancement are gadolinium-based contrast agents (GBCAs). Such MRI contrast agents shorten the relaxation times of nuclei within body tissues following oral or intravenous administration.

<span class="mw-page-title-main">Gadoteric acid</span> Chemical compound

Gadoteric acid, sold under the brand name Dotarem among others, is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA). It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt (gadoterate meglumine). The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI, which is the source of its clinical utility. Because it has magnetic properties, gadoteric acid develops a magnetic moment when put under a magnetic field, which increases the signal intensity (brightness) of tissues during MRI imaging.

<span class="mw-page-title-main">Secukinumab</span> Monoclonal antibody against IL-17

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

<span class="mw-page-title-main">Dupilumab</span> Drug used to treat allergic diseases

Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis and prurigo nodularis.

Tildrakizumab, sold under the brand names Ilumya and Ilumetri, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.

Flutemetamol (<sup>18</sup>F) Chemical compound

Flutemetamol (18F) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18, used as a diagnostic tool for Alzheimer's disease.

<span class="mw-page-title-main">Aripiprazole lauroxil</span> Chemical compound

Aripiprazole lauroxil, sold under the brand name Aristada, is a long-acting injectable atypical antipsychotic that was developed by Alkermes. It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia. Aripiprazole lauroxil was approved by the U.S. Food and Drug Administration (FDA) on 5 October 2015.

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.

Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a fixed-dose combination medication used as an antibiotic. In 2019, it was approved for use in the United States for the treatment of complicated urinary tract and complicated intra-abdominal infections. It is administered via intravenous injection.

Pertuzumab/trastuzumab/hyaluronidase, sold under the brand name Phesgo, is a fixed-dose combination medication to treat adults with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adults with early HER2-positive breast cancer. It contains pertuzumab, trastuzumab, and hyaluronidase–zzxf. It is injected under the skin via subcutaneous injection in the thigh. In the European Union, Phesgo contains the active ingredients pertuzumab and trastuzumab along with the enzyme vorhyaluronidase alfa.

Pegcetacoplan, sold under the brand name Empaveli, among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria and geographic atrophy of the retina. Pegcetacoplan is a complement inhibitor.

<span class="mw-page-title-main">Piflufolastat F-18</span> Chemical compound

Piflufolastat F-18, sold under the brand name Pylarify among others, is a radioactive diagnostic agent used for positron emission tomography (PET) imaging. It is given by intravenous injection.

Vutrisiran, sold under the brand name Amvuttra, is a medication used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is a double stranded small interfering RNA (siRNA) that interferes with the expression of the transthyretin (TTR) gene. Transthyretin is a serum protein made in the liver whose major function is transport of vitamin A and thyroxine. Rare mutations in the transthyretin gene result in accumulation of large amyloid deposits of misfolded transthyretin molecules most prominently in peripheral nerves and the heart. Patients with hATTR typically present with polyneuropathy or autonomic dysfunction followed by cardiomyopathy which, if untreated, is fatal within 5 to 10 years.

<span class="mw-page-title-main">Gadopiclenol</span> MRI contrast agent

Gadopiclenol, sold under the brand name Elucirem among others, is a contrast agent used with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and in the body. Gadopiclenol is a paramagnetic macrocyclic non-ionic complex of gadolinium.

References

  1. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 Oct 2023.
  2. ↑ Cheng KT (2007). "Gadobutrol" (PDF). Molecular Imaging and Contrast Agent Database (MICAD). PMID   20641787. NBK23589.
  3. ↑ "Bayer in Radiology – Gadavist® (gadobutrol) injection 1 mmol/mL". bayerimaging.com. Retrieved 20 May 2015.
  4. ↑ "FDA approves imaging agent for central nervous system scans" (Press release). U.S. Food and Drug Administration (FDA). March 15, 2011. Retrieved March 31, 2011.
  5. ↑ "U.S. FDA Approves Bayer's Gadavist (Gadobutrol) Injection for MRI of the Central Nervous System" (Press release). Bayer HealthCare Pharmaceuticals. March 14, 2011. Archived from the original on May 2, 2011. Retrieved March 31, 2011.
  6. ↑ "Education for Cardiology Disease Professionals" (PDF). touchcardiology.com. Radcliffecardiology. Archived from the original (PDF) on 28 September 2011. Retrieved 20 May 2015.
  7. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "Gadavist full prescribing information" (PDF). Retrieved 2011-03-14.
  8. ↑ "Viv-Butrol". Vivere Imaging.
  9. 1 2 3 4 5 6 7 8 9 "GadovistProduct Monograph" (PDF). Bayer Inc. August 12, 2016. Retrieved November 11, 2016.[ permanent dead link ]
  10. ↑ "Gadobutrol". DrugBank. 2016-11-19.
  11. 1 2 3 4 5 "Briefing Document for Gadobutrol Injection, NDA 201,277" (PDF). FDA.Gov. Food and Drug Administration. January 21, 2011. Retrieved November 11, 2016.
  12. 1 2 "Gadavist (gadobutrol) FDA Approval History". www.drugs.com. Retrieved 2016-11-19.
  13. ↑ Stinson B (March 6, 2009). "Clinical Review" (PDF). FDA.Gov. FDA. Retrieved November 11, 2016.
  14. ↑ Clinical trial number NCT00709852 for "Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging" at ClinicalTrials.gov
  15. ↑ Clinical trial number NCT01544166 for "Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years " at ClinicalTrials.gov
  16. ↑ Clinical trial number NCT01344447 for "Gadobutrol Enhanced MRA of the Supra-aortic Vessels" at ClinicalTrials.gov
  17. 1 2 US 5980864,Platzek J, Gries H, Weinmann H, Schuhmann-Giampieri G, Press W,"1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them",issued 9 November 1999, assigned to Bayer Intellectual Property GmbH
  18. ↑ "Gadavist® (gadobutrol) injection 1 mmol/mL". Bayer in Radiology. Archived from the original on 2016-10-18. Retrieved 2016-11-20.
  19. ↑ "2016 Price List" (PDF). Bayer-UK. June 16, 2016. Archived from the original (PDF) on November 20, 2016. Retrieved November 19, 2016.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.